Search - tctmd.com

Displaying 101 - 120 of 124

Sort: Relevancy | Date

News Daily News

Many Invasive Procedures, Including Cardiovascular, Up Risk of Infective Endocarditis

Caitlin E. Cox

June 11, 2018

News Daily News

Real-World AV Replacement in France: All Eyes on Mortality as Volumes Go Up and Patient Risk Declines

Yael L. Maxwell

April 10, 2018

News Daily News

ESC Releases New Syncope Guidelines

Shelley Wood

March 20, 2018

News Daily News

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

Shelley Wood

October 10, 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Shelley Wood

September 24, 2017

News Daily News

Implanted Devices May Help Determine Time and Cause of Death When Autopsy Falls Short

Yael L. Maxwell

June 26, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Daily News

FDA Warns of Cybersecurity Holes in Certain Cardiac Devices and Monitoring System

Yael L. Maxwell

January 09, 2017

News Daily News

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

L.A. McKeown

December 13, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Daily News

St. Jude Medical Warns of Rapid, Unexpected, and Potentially Lethal Battery Depletions With ICDs, CRT-Ds

Shelley Wood

October 11, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Conference News TCT 2015

Robotic Systems to Play Greater Role in Cath Lab of the Future

Todd Neale

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Industry News

BioControl Medical Completes Enrollment in the INOVATE-HF Study of the CardioFit® System to Treat Heart Failure

August 27, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Daily News

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

July 07, 2015

News Daily News

CoreValve在高风险患者中的生存益处到2年时依然持续存在

July 07, 2015

Advertisement

Many Invasive Procedures, Including Cardiovascular, Up Risk of Infective Endocarditis

Real-World AV Replacement in France: All Eyes on Mortality as Volumes Go Up and Patient Risk Declines

ESC Releases New Syncope Guidelines

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Implanted Devices May Help Determine Time and Cause of Death When Autopsy Falls Short

FDA Approves Next-Gen CoreValve Evolut PRO Valve

FDA Warns of Cybersecurity Holes in Certain Cardiac Devices and Monitoring System

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

TCTMD’s Top 10 Most Popular Stories for October 2016

St. Jude Medical Warns of Rapid, Unexpected, and Potentially Lethal Battery Depletions With ICDs, CRT-Ds

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Robotic Systems to Play Greater Role in Cath Lab of the Future

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

BioControl Medical Completes Enrollment in the INOVATE-HF Study of the CardioFit® System to Treat Heart Failure

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

El Beneficio sobre la Supervivencia de CoreValve en Pacientes de Alto Riesgo se Mantiene a los 2 Años

CoreValve在高风险患者中的生存益处到2年时依然持续存在

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content